Objective
to determine whether P2Y12 inhibitor monotherapy 3 months after PCI is non-inferior to 12 month DAPT following PCI
Study
open-label multicentre non-inferiority randomised trial (margin 1.8%)
Population
patients undergoing PCI without contra-indication to aspirin, clopidogrel, prasugrel, ticagrelor, everolimus, sirolimus and no active pathological bleeding
Endpoints
composite all-cause death, MI or stroke at 12 months after PCI
Conclusion
P2Y12 monotherapy for 3 months was non-inferior to 12 month DAPT after PCI in terms of major cardiac cerebrovascular events
Hahn et al. JAMA. 2019;321:2428-37
